BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 27812766)

  • 1. Hypoxia-selective inhibition of angiogenesis development by NAMI-A analogues.
    Oszajca M; Collet G; Stochel G; Kieda C; Brindell M
    Biometals; 2016 Dec; 29(6):1035-1046. PubMed ID: 27812766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and X-ray Structural Analysis of the Ruthenium(III) Complex Na[trans-RuCl4(DMSO) (PyrDiaz)], the Diazene Derivative of Antitumor NAMI-Pyr.
    Vajs J; Pevec A; Gazvoda M; Urankar D; Goreshnik E; Polanc S; Košmrlj J
    Acta Chim Slov; 2017 Dec; 64(4):763-770. PubMed ID: 29318318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and chemical-pharmacological characterization of the antimetastatic NAMI-A-type Ru(III) complexes (Hdmtp)[trans-RuCl4(dmso-S)(dmtp)], (Na)[trans-RuCl4(dmso-S)(dmtp)], and [mer-RuCl3(H2O)(dmso-S)(dmtp)] (dmtp = 5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidine).
    Velders AH; Bergamo A; Alessio E; Zangrando E; Haasnoot JG; Casarsa C; Cocchietto M; Zorzet S; Sava G
    J Med Chem; 2004 Feb; 47(5):1110-21. PubMed ID: 14971891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ruthenium anticancer agent KP1019 binds more tightly than NAMI-A to tRNA
    Dwyer BG; Johnson E; Cazares E; McFarlane Holman KL; Kirk SR
    J Inorg Biochem; 2018 May; 182():177-183. PubMed ID: 29501978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Appraisal of the redox behaviour of the antimetastatic ruthenium(III) complex [ImH][RuCl(4)(DMSO)(Im)], NAMI-A.
    Ravera M; Baracco S; Cassino C; Zanello P; Osella D
    Dalton Trans; 2004 Aug; (15):2347-51. PubMed ID: 15278129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The hydrolysis of the anti-cancer ruthenium complex NAMI-A affects its DNA binding and antimetastatic activity: an NMR evaluation.
    Bacac M; Hotze AC; van der Schilden K; Haasnoot JG; Pacor S; Alessio E; Sava G; Reedijk J
    J Inorg Biochem; 2004 Feb; 98(2):402-12. PubMed ID: 14729322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ruthenium antimetastatic agents.
    Alessio E; Mestroni G; Bergamo A; Sava G
    Curr Top Med Chem; 2004; 4(15):1525-35. PubMed ID: 15579094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ru binding to RNA following treatment with the antimetastatic prodrug NAMI-A in Saccharomyces cerevisiae and in vitro.
    Hostetter AA; Miranda ML; DeRose VJ; McFarlane Holman KL
    J Biol Inorg Chem; 2011 Dec; 16(8):1177-85. PubMed ID: 21739255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of Cytotoxicity in Pyridine Analogues of the Anti-metastatic Ru(III) Complex NAMI-A by Ferrocene Functionalization.
    Mu C; Chang SW; Prosser KE; Leung AW; Santacruz S; Jang T; Thompson JR; Yapp DT; Warren JJ; Bally MB; Beischlag TV; Walsby CJ
    Inorg Chem; 2016 Jan; 55(1):177-90. PubMed ID: 26652771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osmium NAMI-A analogues: synthesis, structural and spectroscopic characterization, and antiproliferative properties.
    Cebrián-Losantos B; Krokhin AA; Stepanenko IN; Eichinger R; Jakupec MA; Arion VB; Keppler BK
    Inorg Chem; 2007 Jun; 46(12):5023-33. PubMed ID: 17497853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The hydrolysis mechanism of the anticancer ruthenium drugs NAMI-A and ICR investigated by DFT-PCM calculations.
    Vargiu AV; Robertazzi A; Magistrato A; Ruggerone P; Carloni P
    J Phys Chem B; 2008 Apr; 112(14):4401-9. PubMed ID: 18348562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Control of ligand-exchange processes and the oxidation state of the antimetastatic Ru(III) complex NAMI-A by interactions with human serum albumin.
    Webb MI; Walsby CJ
    Dalton Trans; 2011 Feb; 40(6):1322-31. PubMed ID: 21210063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis, structural characterization, solution chemistry, and preliminary biological studies of the ruthenium(III) complexes [TzH][trans-RuCl4(Tz)2] and [TzH][trans-RuCl4(DMSO)(Tz)].(DMSO), the thiazole analogues of antitumor ICR and NAMI-A.
    Mura P; Camalli M; Messori L; Piccioli F; Zanello P; Corsini M
    Inorg Chem; 2004 Jun; 43(13):3863-70. PubMed ID: 15206867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Water-soluble Ru(II)- and Ru(III)-halide-PTA complexes (PTA=1,3,5-triaza-7-phosphaadamantane): Chemical and biological properties.
    Battistin F; Scaletti F; Balducci G; Pillozzi S; Arcangeli A; Messori L; Alessio E
    J Inorg Biochem; 2016 Jul; 160():180-8. PubMed ID: 26920229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tuning of redox potentials for the design of ruthenium anticancer drugs -- an electrochemical study of [trans-RuCl(4)L(DMSO)](-) and [trans-RuCl(4)L(2)](-) complexes, where L = imidazole, 1,2,4-triazole, indazole.
    Reisner E; Arion VB; Guedes da Silva MF; Lichtenecker R; Eichinger A; Keppler BK; Kukushkin VY; Pombeiro AJ
    Inorg Chem; 2004 Nov; 43(22):7083-93. PubMed ID: 15500346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Albumin binding and ligand-exchange processes of the Ru(III) anticancer agent NAMI-A and its bis-DMSO analogue determined by ENDOR spectroscopy.
    Webb MI; Walsby CJ
    Dalton Trans; 2015 Oct; 44(40):17482-93. PubMed ID: 26174110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo biological activity screening of Ru(III) complexes involving 6-benzylaminopurine derivatives with higher pro-apoptotic activity than NAMI-A.
    Trávníček Z; Matiková-Mal'arová M; Novotná R; Vančo J; Stěpánková K; Suchý P
    J Inorg Biochem; 2011 Jul; 105(7):937-48. PubMed ID: 21536006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hydrolysis of the tumor-inhibiting ruthenium(III) complexes HIm trans-[RuCl4(im)2] and HInd trans-[RuCl4(ind)2] investigated by means of HPCE and HPLC-MS.
    Küng A; Pieper T; Wissiack R; Rosenberg E; Keppler BK
    J Biol Inorg Chem; 2001 Mar; 6(3):292-9. PubMed ID: 11315565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of KP1019 and NAMI-A in tumour-mimetic environments.
    Gransbury GK; Kappen P; Glover CJ; Hughes JN; Levina A; Lay PA; Musgrave IF; Harris HH
    Metallomics; 2016 Aug; 8(8):762-73. PubMed ID: 27460862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of adhesion, migration and of α5β1 integrin in the HCT-116 colorectal cancer cells treated with the ruthenium drug NAMI-A.
    Pelillo C; Mollica H; Eble JA; Grosche J; Herzog L; Codan B; Sava G; Bergamo A
    J Inorg Biochem; 2016 Jul; 160():225-35. PubMed ID: 26961176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.